LEUKEMIA AND HEAD AND NECK CANCER DRUGS NOT APPROVED FOR NHS ENGLAND.
People diagnosed with head and neck cancer, or leukaemia are currently set to miss out on new cancer drugs.
Pembrolizumab (Keytruda) is thought to aid the body’s immune system in recognising and killing cancer cells, while Gilteritinib (Xospata) works to block chemical signals that would otherwise help a cancer grow. Decisions are set to be reviewed by the National Institute for Health and Care Excellence (NICE) later this year, once more data is collected from clinical trials.
Read the full article here: https://medicalxpress.com/news/2020-01-leukemia-neck-cancer-drugs-nhs.html